Rejected from Gastroenterology? The 7 Best Journals to Submit Next

Clinical significance first. Every paper Gastroenterology publishes needs to matter to gastroenterologists. The editors aren't asking whether the science is good. They're asking whether it changes how GI physicians think about a disease, a treatment, or a diagnostic approach. Pure basic science without a clinical connection struggles here.

Statistical rigor. Gastroenterology's statistical editors are among the most demanding in medical publishing. Observational studies need propensity matching or instrumental variable analysis. Clinical trials need prespecified primary endpoints and appropriate multiplicity adjustments. If your statistical approach was questioned, the next journal's reviewers will likely raise the same issues.

Breadth across the GI tract. The journal publishes across all GI subspecialties: esophageal disorders, IBD, hepatology, pancreatic disease, GI motility, colorectal cancer, and microbiome science. This breadth means every paper competes against excellent work from other subspecialties for limited space.

"The clinical relevance of these findings is unclear." Your paper has interesting biological data, but the editors can't see how it connects to patient care. This is a framing problem. The biology might genuinely matter, but the manuscript didn't make the case.

"Large cohort study with inherent design limitations." You analyzed a large retrospective database, but Gastroenterology's statistical reviewers flagged confounders, selection bias, or missing data that undermine the conclusions. The journal is increasingly skeptical of retrospective analyses unless the methodology is airtight.

"We suggest transfer to Clinical Gastroenterology and Hepatology." The editors believe your paper is publishable and clinically relevant but doesn't quite clear Gastroenterology's selectivity threshold. CGH is the AGA's companion journal, and a transfer preserves your review history.

"The hepatology content is better addressed by a liver-focused journal." Gastroenterology publishes hepatology research, but liver papers compete against the full spectrum of GI topics. If your paper is entirely hepatology, journals like Hepatology or Journal of Hepatology give it a dedicated audience.

"We have received multiple submissions on this topic recently." Especially true for hot topics like GLP-1 agonists and GI effects, AI in endoscopy, or microbiome therapeutics. Your paper may be excellent but arrived during a period of editorial saturation.

Gastroenterology operates within a publisher ecosystem that includes:

• Clinical Gastroenterology and Hepatology (CGH) (IF ~12) - Clinical GI and hepatology, AGA companion
• Cellular and Molecular Gastroenterology and Hepatology (CMGH) (IF ~8) - Basic and translational GI science
• Gastro Hep Advances (IF ~3) - Newer open-access venue, broader acceptance

CGH is the most common transfer destination and a genuinely strong journal in its own right. CMGH is excellent for basic science papers that Gastroenterology found "too translational" for their clinical audience.

Before choosing your next journal, a Gastroenterology manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. Gut

Gut (BMJ) is Gastroenterology's direct competitor and the other pillar of GI publishing. The two journals have similar IFs and similar selectivity, but their editorial philosophies differ in meaningful ways. Where Gastroenterology emphasizes clinical significance for practicing gastroenterologists, Gut leans more heavily toward translational research with mechanistic depth.

If Gastroenterology rejected your paper for being "too translational" or focused too heavily on molecular mechanisms, Gut's editors may find that same depth attractive. Conversely, if Gastroenterology wanted more clinical data and you can't provide it, Gut might accept the biological story on its own merits.

Best for: Translational GI research with mechanistic depth, microbiome science, GI mucosal immunology.

2. Lancet Gastroenterology and Hepatology

For practice-changing clinical GI evidence, this Lancet specialty journal is the most ambitious alternative to Gastroenterology. With an IF around 35, it publishes landmark clinical trials, large prospective studies, and GI research with global policy implications. The acceptance rate is lower than Gastroenterology's, so only submit here if you're confident the clinical evidence is at the highest tier.

Lancet Gastroenterology also publishes GI epidemiology and health services research, which Gastroenterology handles less frequently. If your paper addresses GI disease burden or healthcare delivery patterns, the Lancet perspective may be a better match.

Best for: Large clinical GI trials, GI epidemiology with global scope, practice-changing therapeutic evidence.

3. American Journal of Gastroenterology

AJG is the flagship of the American College of Gastroenterology and publishes clinically focused GI research. The journal is slightly less selective than Gastroenterology (acceptance rate around 15%) and values clinical contributions that are directly relevant to practicing gastroenterologists.

AJG is a particularly good option for clinical research that Gastroenterology found solid but not impactful enough. Endoscopy outcomes, clinical management studies, and practice-pattern analyses are core content areas. The journal also publishes strong observational studies and real-world evidence that Gastroenterology might consider "not rigorous enough" for their standards.

Best for: Clinical gastroenterology, endoscopy research, practice-oriented GI studies, clinical management outcomes.

4. Clinical Gastroenterology and Hepatology

CGH is Gastroenterology's companion journal within the AGA family. If you received a transfer offer from Gastroenterology, CGH is the likely destination. The journal publishes clinical research across GI and hepatology, with particular strength in diagnostic studies, clinical outcomes, and systematic reviews.

Even without a formal transfer, CGH is worth considering independently. The journal has its own editorial identity, with a focus on research that helps gastroenterologists make better clinical decisions. The IF around 12 reflects its position as one of the top clinical GI journals.

Best for: Clinical GI research, diagnostic studies, systematic reviews, clinical outcomes across GI and hepatology.

5. Hepatology

For liver-focused research, Hepatology (AASLD journal) is the standard venue. If Gastroenterology rejected your paper because the hepatology component was dominant, Hepatology's dedicated liver readership is where the paper should go. The journal covers all aspects of liver disease: NAFLD/NASH, viral hepatitis, liver fibrosis, hepatocellular carcinoma, and transplant hepatology.

Best for: NAFLD/NASH, viral hepatitis, liver fibrosis, HCC, transplant hepatology, all liver-focused research.

6. Alimentary Pharmacology and Therapeutics

AP&T focuses on GI therapeutics and pharmacology, making it an excellent fit for drug therapy studies, pharmacokinetic research, and treatment management studies across the GI tract. The journal has a higher acceptance rate (around 20%) and provides a focused readership for papers about GI drug treatment.

If your Gastroenterology submission was a therapeutic study that the editors found too narrow for their broad GI readership, AP&T's audience specifically cares about GI drug therapy.

Best for: GI drug therapy, pharmacokinetics, therapeutic management, treatment outcome studies.

7. Inflammatory Bowel Diseases

For IBD-specific research, this dedicated journal provides the most targeted readership. Gastroenterology publishes excellent IBD research, but IBD papers compete with papers from every other GI subspecialty for limited space. In Inflammatory Bowel Diseases (published by the Crohn's and Colitis Foundation), your IBD paper gets evaluated by IBD specialists without that cross-subspecialty competition.

The journal covers all aspects of IBD: pathogenesis, medical therapy, surgical management, biomarkers, and quality of life. It's the right venue for IBD research that's excellent within the IBD field but too specialized for a general GI journal.

Best for: Crohn's disease, ulcerative colitis, IBD therapeutics, IBD biomarkers, IBD pathogenesis, IBD outcomes.

Translational GI paper rejected? Try Gut (values mechanistic depth more than Gastroenterology), then CMGH (AGA's translational journal) for basic science work.

Clinical trial rejected? AJG for solid clinical GI trials that didn't clear the top-tier bar. CGH if the trial has a diagnostic or management angle. Lancet Gastroenterology if the trial is large enough to be practice-changing.

Hepatology paper rejected? Go to Hepatology or Journal of Hepatology rather than another general GI journal. Your liver paper will be evaluated by liver specialists.

IBD paper rejected? Inflammatory Bowel Diseases for IBD-specific research. For IBD trials with broad GI implications, Gut or AJG may still be appropriate.

Microbiome paper rejected? Gut often values microbiome work more than Gastroenterology, especially when there's mechanistic depth. Gut Microbes is the specialty alternative for microbiome-focused papers.

Strengthen the "so what?" statement. Gastroenterology rejections often come down to unclear clinical relevance. Before resubmitting, make sure your abstract and introduction explicitly state what your findings mean for patient care. Don't make the reader work to understand why the paper matters.

Fix the statistics. If Gastroenterology's statistical editor flagged concerns, address them before submitting anywhere else. Common issues in GI research include immortal time bias in cohort studies, competing risks in survival analyses, and multiplicity in subgroup analyses. A biostatistician consult is worth the investment.

Address the hepatology-GI question. If your paper spans both GI and hepatology topics, pick one focus for the resubmission. Trying to be both a GI paper and a hepatology paper often results in not being compelling enough for either audience.

Update the literature. GI publishing moves quickly, especially in areas like IBD biologics, GI oncology, and microbiome therapeutics. If your manuscript references landscape-level studies from 2023 or earlier, make sure the introduction reflects the current evidence base.

The difference between a Gastroenterology paper and a CGH paper is often about framing and competitive timing rather than underlying quality. Before your next submission, run your revised manuscript through a manuscript scope and readiness check to check scope alignment, structural completeness, and formatting compliance. Matching the right paper to the right journal saves months of unnecessary review cycles and gets your research in front of the gastroenterologists who need to see it.

Resubmit to the same tier if:

• Reviewers praised the science but identified fixable issues
• You can address concerns within 2-3 months

Move to a different journal if:

• The rejection cited scope mismatch, not quality
• Your timeline needs a decision within 2-3 months

Reframe before resubmitting if:

• Reviewers found fundamental methodology concerns
• New experiments are needed to support the claims

In our pre-submission review work with manuscripts targeting Gastroenterology, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Clinical significance framed at the subspecialty level rather than the field level. Gastroenterology is the flagship journal of the AGA and expects findings that matter across gastroenterology and hepatology, not just within one disease area. We see this failure as the most common pattern in Gastroenterology desk rejections we review: well-executed studies in IBD, NAFLD, or colorectal cancer where the significance is most legible to specialists in that one condition without clear implications for the broader GI field. In our review of Gastroenterology submissions, we find that editors consistently require the finding to teach something applicable across the journal's scope.

Basic science without a direct connection to GI clinical disease. Gastroenterology expects that mechanistic papers connect to a patient population. Papers characterizing intestinal epithelial cell biology, microbiome function, or hepatocyte signaling without connecting to a human disease process or clinical phenotype are consistently redirected to cellular biology journals. We see this pattern in basic science manuscripts we review targeting Gastroenterology: mechanistically rigorous work where the human disease connection is speculative or framed as future directions.

Statistical concerns visible from the design or analysis. Gastroenterology's statistical review is thorough. We see this failure regularly in manuscripts we review: cohort studies or registry analyses presenting association data where confounding is acknowledged but not adequately addressed, or where the conclusions draw causal language from observational evidence. Papers with large sample sizes but significant unmeasured confounding face consistent reviewer concerns.

Incremental follow-up within a well-characterized GI research program. Gastroenterology editors screen explicitly for papers that represent genuine advances rather than extensions of prior work. Papers from the same research group demonstrating that a known GI pathway operates in an additional disease context, or presenting the next phase of a mechanistic story already published, face desk rejection for limited incremental advance.

SciRev community data for Gastroenterology confirms desk rejections typically arrive within days, with post-review first decisions within 6-8 weeks, consistent with the editorial pace the AGA maintains across its flagship portfolio.